1
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Bailes M, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Barthelmy SD, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bossie K, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia H, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung AKW, Chung S, Ciani G, Ciolfi R, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, De S, DeBra D, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Dergachev V, De Rosa R, DeRosa RT, De Rossi C, DeSalvo R, de Varona O, Devenson J, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Renzo F, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Douglas R, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Ducrot M, Dudi R, Dupej P, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenstein RA, Essick RC, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finstad D, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fries EM, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard H, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia-Quiros C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gehrels N, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glover L, Goetz E, Goetz R, Gomes S, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Hinderer T, Ho WCG, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Hu YM, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Kastaun W, Katolik M, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Kent C, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimbrell SJ, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Larson SL, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leon E, Leonardi M, Leroy N, Letendre N, Levin Y, Li TGF, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsh P, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Marx JN, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIntyre G, McIver J, McManus DJ, McNeill L, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller BB, Miller J, Millhouse M, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Moggi A, Mogushi K, Mohan M, Mohapatra SRP, Molina I, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Morriss SR, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Newton G, Ng KKY, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Noack A, Nocera F, Nolting D, North C, Nuttall LK, Oberling J, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poe M, Poggiani R, Popolizio P, Porter EK, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Reyes SD, Ricci F, Ricker PM, Rieger S, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sonnenberg JA, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Wessel EK, Weßels P, Westerweck J, Westphal T, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford J, Wong KWK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral. PHYSICAL REVIEW LETTERS 2017; 119:161101. [PMID: 29099225 DOI: 10.1103/physrevlett.119.161101] [Citation(s) in RCA: 879] [Impact Index Per Article: 109.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Indexed: 05/21/2023]
Abstract
On August 17, 2017 at 12∶41:04 UTC the Advanced LIGO and Advanced Virgo gravitational-wave detectors made their first observation of a binary neutron star inspiral. The signal, GW170817, was detected with a combined signal-to-noise ratio of 32.4 and a false-alarm-rate estimate of less than one per 8.0×10^{4} years. We infer the component masses of the binary to be between 0.86 and 2.26 M_{⊙}, in agreement with masses of known neutron stars. Restricting the component spins to the range inferred in binary neutron stars, we find the component masses to be in the range 1.17-1.60 M_{⊙}, with the total mass of the system 2.74_{-0.01}^{+0.04}M_{⊙}. The source was localized within a sky region of 28 deg^{2} (90% probability) and had a luminosity distance of 40_{-14}^{+8} Mpc, the closest and most precisely localized gravitational-wave signal yet. The association with the γ-ray burst GRB 170817A, detected by Fermi-GBM 1.7 s after the coalescence, corroborates the hypothesis of a neutron star merger and provides the first direct evidence of a link between these mergers and short γ-ray bursts. Subsequent identification of transient counterparts across the electromagnetic spectrum in the same location further supports the interpretation of this event as a neutron star merger. This unprecedented joint gravitational and electromagnetic observation provides insight into astrophysics, dense matter, gravitation, and cosmology.
Collapse
|
|
8 |
879 |
2
|
Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 2000; 19:348-52. [PMID: 10832697 DOI: 10.1097/00003226-200005000-00018] [Citation(s) in RCA: 459] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
PURPOSE To identify the potential antiangiogenic and antiinflammatory proteins expressed in human amniotic membrane tissue. METHODS Human amniotic epithelial and mesenchymal cells were isolated from human amniotic membranes by sequential trypsin and collagenase digestion. Total RNAs were harvested from freshly obtained human amniotic epithelial and mesenchymal cells. Antiangiogenic and antiinflammatory proteins were detected by the reverse transcriptase-polymerase chain reaction (RT-PCR) technique and further confirmed by DNA sequencing of PCR-amplified transcripts. The distribution of tissue inhibitors of metalloproteinase (TIMPs) were studied further by immunohistochemistry performed on paraffin-embedded amniotic membrane tissue. RESULTS RT-PCR results showed that both human amniotic epithelial and mesenchymal cells express interleukin-1 receptor antagonist, all four TIMPs, collagen XVIII, and interleukin-10. Thrombospondin-1 was expressed in all of the epithelial cell specimens and in one out of five mesenchymal cell specimens. Furthermore, immunohistochemistry studies performed on freshly prepared amniotic membrane confirmed that all members of the TIMP family were present in epithelial and mesenchymal cells as well as in the compact layer of the amniotic stroma. In cryopreserved amniotic membranes, positive staining was seen in residual amniotic cells and stroma. CONCLUSIONS Human amniotic membrane epithelial and mesenchymal cells express various antiangiogenic and antiinflammatory proteins. Some of those proteins also were found in amniotic membrane stroma. These findings may explain in part the antiangiogenic and antiinflammatory effects of amniotic membrane transplantation.
Collapse
|
|
25 |
459 |
3
|
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, Park CH, Park K. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12:349-52. [PMID: 11332147 DOI: 10.1023/a:1011144911781] [Citation(s) in RCA: 227] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The present study aimed to analyse the treatment outcome of four cycles of CHOP (cyclophosphamide-vincristine-doxorubicin-prednisolone) followed by involved field radiation therapy (IF RT) for the treatment of stage I-II nasal natural killer (NK)/T-cell lymphoma. From March 1995 to December 1999, 17 patients (median age 41 years; range 30-66) with localized nasal NK/T-cell lymphoma were enrolled. B symptoms were noted in five patients (31%). Sixteen of seventeen patients (94%) were of low risk when classified according to the International Prognostic Index (IPI). The treatment plan consisted of four cycles of CHOP chemotherapy followed by IF RT of 45 Gy. Two patients received radiation during the first or second cycle of CHOP because of bleeding from the primary tumour site. Both patients achieved complete responses (CRs). In the remaining 15 patients, after 4 cycles of CHOP, 6 CRs and 3 partial responses (PRs) were achieved (53% of response rate). IF RT was given to six patients (four in CR, one in PR and one in PD), and all six patients achieved CR. Overall, CR was achieved in 10 of 17 patients (58%). The planned sequential chemoradiotherapy was completed in only 6 of 17 patients (35%) because of the progression during chemotherapy. None of the patients who achieved CR experienced relapse of lymphoma during follow-up. The estimated overall three-year survival rate was 59%. In univariate analysis, B symptoms and stage were significant prognostic factors for response and overall survival (P < 0.05). The present study suggests that four cycles of CHOP followed by IF RT is not satisfactory for treating patients with localized nasal NK/T-cell lymphoma, and that further exploration for improved therapy is needed.
Collapse
|
|
24 |
227 |
4
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, AultONeal K, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bawaj M, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Bogaert G, Bohe A, Bondu F, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brown NM, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerboni Baiardi L, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen Y, Cheng HP, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung AKW, Chung S, Ciani G, Ciolfi R, Cirelli CE, Cirone A, Clara F, Clark JA, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Colla A, Collette CG, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, De S, DeBra D, Deelman E, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Denker T, Dent T, Dergachev V, De Rosa R, DeRosa RT, DeSalvo R, Devenson J, Devine RC, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Renzo F, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Douglas R, Dovale Álvarez M, Downes TP, Drago M, Drever RWP, Driggers JC, Du Z, Ducrot M, Duncan J, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenstein RA, Essick RC, Etienne ZB, Etzel T, Evans M, Evans TM, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fehrmann H, Feicht J, Fejer MM, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fisher RP, Flaminio R, Fletcher M, Fong H, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fries EM, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard H, Gabel M, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garufi F, Gaudio S, Gaur G, Gayathri V, Gehrels N, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glover L, Goetz E, Goetz R, Gomes S, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Hall BR, Hall ED, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Henry J, Heptonstall AW, Heurs M, Hild S, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hu YM, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Ingram DR, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Kent C, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim W, Kim WS, Kim YM, Kimbrell SJ, King EJ, King PJ, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li TGF, Libson A, Littenberg TB, Liu J, Lo RKL, Lockerbie NA, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Maros E, Martelli F, Martellini L, Martin IW, Martynov DV, Marx JN, Mason K, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mayani R, Mazumder N, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIntyre G, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Mezzani F, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moggi A, Mohan M, Mohapatra SRP, Montani M, Moore BC, Moore CJ, Moraru D, Moreno G, Morriss SR, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muniz EAM, Murray PG, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Nelemans G, Nelson TJN, Neri M, Nery M, Neunzert A, Newport JM, Newton G, Ng KKY, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Noack A, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Oberling J, Ochsner E, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Paris HR, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pitkin M, Poggiani R, Popolizio P, Porter EK, Post A, Powell J, Prasad J, Pratt JWW, Predoi V, Prestegard T, Prijatelj M, Principe M, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Qin J, Qiu S, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rakhmanov M, Ramirez KE, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Rew H, Reyes SD, Ricci F, Ricker PM, Rieger S, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Ryan K, Rynge M, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sandberg V, Sandeen B, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheuer J, Schmidt E, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shao L, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer A, Singer LP, Singh A, Singh R, Singhal A, Sintes AM, Slagmolen BJJ, Smith B, Smith JR, Smith RJE, Son EJ, Sonnenberg JA, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stephens BC, Stevenson SP, Stone R, Strain KA, Stratta G, Strigin SE, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Talukder D, Tanner DB, Tápai M, Taracchini A, Taylor JA, Taylor R, Theeg T, Thomas EG, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torrie CI, Töyrä D, Travasso F, Traylor G, Trifirò D, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tuyenbayev D, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahi K, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Voss DV, Vousden WD, Vyatchanin SP, Wade AR, Wade LE, Wade M, Wald RM, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang M, Wang YF, Wang Y, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Wessel EK, Weßels P, Westphal T, Wette K, Whelan JT, Whiting BF, Whittle C, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford J, Wong KWK, Worden J, Wright JL, Wu DS, Wu G, Yam W, Yamamoto H, Yancey CC, Yap MJ, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu XJ, Zimmerman A, Zucker ME, Zweizig J. GW170104: Observation of a 50-Solar-Mass Binary Black Hole Coalescence at Redshift 0.2. PHYSICAL REVIEW LETTERS 2017; 118:221101. [PMID: 28621973 DOI: 10.1103/physrevlett.118.221101] [Citation(s) in RCA: 220] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Indexed: 05/21/2023]
Abstract
We describe the observation of GW170104, a gravitational-wave signal produced by the coalescence of a pair of stellar-mass black holes. The signal was measured on January 4, 2017 at 10∶11:58.6 UTC by the twin advanced detectors of the Laser Interferometer Gravitational-Wave Observatory during their second observing run, with a network signal-to-noise ratio of 13 and a false alarm rate less than 1 in 70 000 years. The inferred component black hole masses are 31.2_{-6.0}^{+8.4}M_{⊙} and 19.4_{-5.9}^{+5.3}M_{⊙} (at the 90% credible level). The black hole spins are best constrained through measurement of the effective inspiral spin parameter, a mass-weighted combination of the spin components perpendicular to the orbital plane, χ_{eff}=-0.12_{-0.30}^{+0.21}. This result implies that spin configurations with both component spins positively aligned with the orbital angular momentum are disfavored. The source luminosity distance is 880_{-390}^{+450} Mpc corresponding to a redshift of z=0.18_{-0.07}^{+0.08}. We constrain the magnitude of modifications to the gravitational-wave dispersion relation and perform null tests of general relativity. Assuming that gravitons are dispersed in vacuum like massive particles, we bound the graviton mass to m_{g}≤7.7×10^{-23} eV/c^{2}. In all cases, we find that GW170104 is consistent with general relativity.
Collapse
|
|
8 |
220 |
5
|
Khouri NF, Stitik FP, Erozan YS, Gupta PK, Kim WS, Scott WW, Hamper UM, Mann RB, Eggleston JC, Baker RR. Transthoracic needle aspiration biopsy of benign and malignant lung lesions. AJR Am J Roentgenol 1985; 144:281-8. [PMID: 3871271 DOI: 10.2214/ajr.144.2.281] [Citation(s) in RCA: 203] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Transthoracic needle aspiration biopsy (TNAB) of lung lesions is a well established procedure for diagnosing lung lesions. The emphasis in the literature has been on diagnosing malignant lesions with an accuracy rate greater than 90% frequently reported. Experience with 650 patients showed that TNAB can diagnose malignant lesions in 95% of patients with cancer, and more importantly that TNAB can identify benign lesions in 88% of patients with such lesions. In this patient population, 22% of undiagnosed, noncalcified lung lesions were benign. Therefore, TNAB of lung lesions has a potential of limiting diagnostic thoracotomies to fewer than 8% of patients with lung lesions, significantly reducing the number of unnecessary thoracotomies for benign disease. The success of TNAB is affected by equipment, technique, skill, and experience and is enhanced by close cooperation among the various physicians involved.
Collapse
|
|
40 |
203 |
6
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Boetzel Y, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia HY, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Derby J, Dergachev V, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Goetz E, Goetz R, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hamilton HF, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Hernandez FJ, Heurs M, Hild S, Hinderer T, Ho WCG, Hoak D, Hochheim S, Hofman D, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Iess A, Indik N, Ingram C, Inta R, Intini G, Irwin BS, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Johnson DS, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana NV, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Key JS, Khalili FY, Khamesra B, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Landry P, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li TGF, Li X, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Mills J, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Mogushi K, Mohan M, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Ng KY, Ng S, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, North C, Nuttall LK, Obergaulinger M, Oberling J, O'Brien BD, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perego A, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poggiani R, Popolizio P, Porter EK, Possenti L, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Principe M, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Ricker PM, Riemenschneider GM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Robson T, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sarin N, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Shen H, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Slaven-Blair TJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Steltner B, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trovato A, Trozzo L, Tsang KW, Tse M, Tso R, Tsuna D, Tsukada L, Tuyenbayev D, Ueno K, Ugolini D, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westerweck J, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong WK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yam W, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zlochower Y, Zucker ME, Zweizig J. GW170817: Measurements of Neutron Star Radii and Equation of State. PHYSICAL REVIEW LETTERS 2018; 121:161101. [PMID: 30387654 DOI: 10.1103/physrevlett.121.161101] [Citation(s) in RCA: 197] [Impact Index Per Article: 28.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 07/25/2018] [Indexed: 06/08/2023]
Abstract
On 17 August 2017, the LIGO and Virgo observatories made the first direct detection of gravitational waves from the coalescence of a neutron star binary system. The detection of this gravitational-wave signal, GW170817, offers a novel opportunity to directly probe the properties of matter at the extreme conditions found in the interior of these stars. The initial, minimal-assumption analysis of the LIGO and Virgo data placed constraints on the tidal effects of the coalescing bodies, which were then translated to constraints on neutron star radii. Here, we expand upon previous analyses by working under the hypothesis that both bodies were neutron stars that are described by the same equation of state and have spins within the range observed in Galactic binary neutron stars. Our analysis employs two methods: the use of equation-of-state-insensitive relations between various macroscopic properties of the neutron stars and the use of an efficient parametrization of the defining function p(ρ) of the equation of state itself. From the LIGO and Virgo data alone and the first method, we measure the two neutron star radii as R_{1}=10.8_{-1.7}^{+2.0} km for the heavier star and R_{2}=10.7_{-1.5}^{+2.1} km for the lighter star at the 90% credible level. If we additionally require that the equation of state supports neutron stars with masses larger than 1.97 M_{⊙} as required from electromagnetic observations and employ the equation-of-state parametrization, we further constrain R_{1}=11.9_{-1.4}^{+1.4} km and R_{2}=11.9_{-1.4}^{+1.4} km at the 90% credible level. Finally, we obtain constraints on p(ρ) at supranuclear densities, with pressure at twice nuclear saturation density measured at 3.5_{-1.7}^{+2.7}×10^{34} dyn cm^{-2} at the 90% level.
Collapse
|
|
7 |
197 |
7
|
Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS, Song KS. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17:1216-9. [PMID: 11491167 DOI: 10.1183/09031936.01.99055301] [Citation(s) in RCA: 192] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Idiopathic pulmonary fibrosis (IPF) was reported to be associated with increased risk of lung cancer as a result of the occurrence of atypical or dysplastic epithelial changes in fibrosis which progressed to invasive malignancy. In that situation, the cancer will develop in the area of major fibrosis. To investigate the direct relationship between fibrosis and cancer development, the real concordance rate of the two lesions in the chest computed tomography (CT) was analysed and compared to the histological types of lung cancer. The subjects included 63 patients with combined lung cancer and IPF (IPF-CA), 218 patients with lone IPF, and 2,660 patients with primary lung cancer. All patients were diagnosed at Asan Medical Center during the same period. The age, percentage of smokers, and the male sex were significantly higher in IPF-CA compared with lone IPF. The odds ratio of smoking was 2.71 compared to nonsmoking IPF controls. In IPF-CA, 56% of the cancer was located in the periphery of the lung and 52% in the upper lobe. The majority of the cancers (64%) were found in the nonfibrotic area at chest CT. The most frequent cell type was squamous cell carcinoma (35%), and there was no significant difference in the cancer cell type between IPF-CA and total lung cancer population. These findings suggest that in combined lung cancer and idiopathic pulmonary fibrosis patients, the features of the lung cancer are similar to the total lung cancer population.
Collapse
|
|
24 |
192 |
8
|
Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS. Comparison of two commercial interferon- assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28:24-30. [PMID: 16611658 DOI: 10.1183/09031936.06.00016906] [Citation(s) in RCA: 178] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The clinical usefulness of ex vivo interferon-gamma assays may largely depend on the assay format and epidemiological status of tuberculosis (TB) in the region studied. From July 2004 to June 2005 a prospective comparison study was undertaken at a tertiary referral hospital in South Korea. The results of tuberculin skin tests (TST) and the commercially available QuantiFERON-TB Gold (QFT-G) and T SPOT-TB (SPOT) assays were compared in an intermediate TB-burden country. Of the 224 participants studied, results from all three tests (TST, QFT-G, and SPOT) were available in 218; 87 with active TB and 131 at a low risk for TB. Using 10 mm as a cut-off for TST, SPOT sensitivity (96.6%) was significantly higher than that seen for TST (66.7%) and QFT-G (70.1%). QFT-G showed superior specificity over TST (91.6 versus 78.6%). Although the specificity of QFT-G was higher than that of SPOT (91.6 versus 84.7%), the difference was not statistically significant. Whilst some differences were found in the performance of the two commercialised interferon-gamma assays, they seemed to be superior in their detection of Mycobacterium tuberculosis infection compared with tuberculin skin tests. The most appropriate choice of interferon-gamma assay to use may depend on the clinical setting.
Collapse
|
|
19 |
178 |
9
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Barthelmy SD, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bossie K, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia H, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung AKW, Chung S, Ciani G, Ciolfi R, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, De S, DeBra D, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Dergachev V, De Rosa R, DeRosa RT, De Rossi C, DeSalvo R, de Varona O, Devenson J, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Renzo F, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Douglas R, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Ducrot M, Dupej P, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenstein RA, Essick RC, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finstad D, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fries EM, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard H, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia-Quiros C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gehrels N, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glover L, Goetz E, Goetz R, Gomes S, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Hinderer T, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hu YM, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Kent C, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimbrell SJ, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li TGF, Linker SD, Littenberg TB, Liu J, Lo RKL, Lockerbie NA, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsh P, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIntyre G, McIver J, McManus DJ, McNeill L, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller BB, Miller J, Millhouse M, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Moggi A, Mogushi K, Mohan M, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Morriss SR, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Newton G, Ng KKY, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Noack A, Nocera F, Nolting D, North C, Nuttall LK, Oberling J, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poe M, Poggiani R, Popolizio P, Porter EK, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Reyes SD, Ricci F, Ricker PM, Rieger S, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sonnenberg JA, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Wessel EK, Weßels P, Westerweck J, Westphal T, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford J, Wong KWK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW170814: A Three-Detector Observation of Gravitational Waves from a Binary Black Hole Coalescence. PHYSICAL REVIEW LETTERS 2017; 119:141101. [PMID: 29053306 DOI: 10.1103/physrevlett.119.141101] [Citation(s) in RCA: 163] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2017] [Indexed: 05/21/2023]
Abstract
On August 14, 2017 at 10∶30:43 UTC, the Advanced Virgo detector and the two Advanced LIGO detectors coherently observed a transient gravitational-wave signal produced by the coalescence of two stellar mass black holes, with a false-alarm rate of ≲1 in 27 000 years. The signal was observed with a three-detector network matched-filter signal-to-noise ratio of 18. The inferred masses of the initial black holes are 30.5_{-3.0}^{+5.7}M_{⊙} and 25.3_{-4.2}^{+2.8}M_{⊙} (at the 90% credible level). The luminosity distance of the source is 540_{-210}^{+130} Mpc, corresponding to a redshift of z=0.11_{-0.04}^{+0.03}. A network of three detectors improves the sky localization of the source, reducing the area of the 90% credible region from 1160 deg^{2} using only the two LIGO detectors to 60 deg^{2} using all three detectors. For the first time, we can test the nature of gravitational-wave polarizations from the antenna response of the LIGO-Virgo network, thus enabling a new class of phenomenological tests of gravity.
Collapse
|
|
8 |
163 |
10
|
Hong JY, Lee HJ, Piedra PA, Choi EH, Park KH, Koh YY, Kim WS. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis 2001; 32:1423-9. [PMID: 11317242 DOI: 10.1086/320146] [Citation(s) in RCA: 152] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2000] [Revised: 09/18/2000] [Indexed: 02/04/2023] Open
Abstract
On occasion, outbreaks of infection with adenovirus types 3, 7, and 21 cause severe lower respiratory tract infections (LRTIs) in children. From 1990 to 1998, all cases of LRTI due to adenovirus at the Seoul National University Children's Hospital, Seoul, Korea, were reviewed. Adenoviruses were recovered from nasal aspirate specimens of 87 (5.9%) of 1472 children with LRTI. The principal adenovirus serotypes were type 2 (13 [15%] of 87 strains), type 3 (13 [15%]), and type 7 (36 [41%]). Of the 87 infections, 62 (71%) occurred in children <2 years of age, and 81 (94%) occurred in children <5 years of age. Infections due to types 3 and 7 occurred during epidemics, whereas infections due to type 2 occurred sporadically. For patients who were infected with types 3 and 7, extrapulmonary abnormalities were more common and homogeneous consolidation and pleural effusion were frequently identified on radiographs. The mortality rate was 12% overall and 19% among patients who were infected with type 7. Residual sequelae were identified in 6 (50%) of 12 patients who were infected with type 3 and in 9 (25%) of 36 who were infected with type 7. The data confirm that adenovirus types 3 and 7 can cause epidemics of severe LRTI in young children. Epidemics of LRTIs caused by adenovirus types 3 and 7 in Korea have not been described in reports published elsewhere.
Collapse
|
|
24 |
152 |
11
|
Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011; 32:382-7. [PMID: 21252041 DOI: 10.3174/ajnr.a2286] [Citation(s) in RCA: 138] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Methylation of the MGMT gene promoter is associated with a favorable prognosis in adult patients with GBM treated with TMZ. We determined the incidence of pseudoprogression according to the MGMT methylation status and the potential value of DSC perfusion MR images for predicting pseudoprogression. MATERIALS AND METHODS New or enlarged enhancing lesions after CCRT in adult patients with newly diagnosed GBMs were prospectively assessed by measuring their rCBV by using DSC perfusion MR images. Tumor tissue was assayed to determine MGMT promoter methylation status. All patients were regularly followed up at an interval of 2 months by MR images, including DSC perfusion MR images. RESULTS Ninety eligible patients were enrolled in this study. After CCRT, new or enlarged enhanced lesions were found in 59 of 90 patients, which were subsequently classified as pseudoprogression (26 patients, 28.9%) and real progression (33 patients, 36.7%). Overall, there was a significant difference in the mean rCBV between pseudoprogression and real tumor progression (P = .003). The ROC curve revealed that an rCBV ratio >1.47 had an 81.5% sensitivity and a 77.8% specificity. The unmethylated MGMT promoter group had a significant difference of mean rCBV between pseudoprogression and real progression (P = .009), though the methylated MGMT promoter group had no significant difference (P = .258). CONCLUSIONS The current study suggests that rCBV measured by DSC perfusion MR images has a differential impact on the predictability of pseudoprogression in patients with GBM.
Collapse
|
Research Support, Non-U.S. Gov't |
14 |
138 |
12
|
Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH, Park K. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005; 92:1226-30. [PMID: 15798768 PMCID: PMC2361983 DOI: 10.1038/sj.bjc.6602502] [Citation(s) in RCA: 138] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis. One half of patients presented with poor performance status (ECOG ⩾2); 46% of patients were categorised as high intermediate or high-risk group according to IPI; and 46% of patients were diagnosed at advanced stage. The median survival for 26 patients with nasal-type NK/T cell lymphoma was 7.4 months (95% CI, 0.1, 16.9). The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised disease and 0% CR rate in advanced disease. After a median follow-up of 24.4 months (range 3.1–99.0) in patients with localised disease who had achieved a CR (range 29.6–165.7), three patients (50.0%) developed disease recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure. The predictive factors for poor survival were of age greater than 60, advanced stage and poor performance in multivariate analysis. In conclusion, Nasal-type NK/T cell lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients.
Collapse
|
Journal Article |
20 |
138 |
13
|
Park SB, You JO, Park HY, Haam SJ, Kim WS. A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics. Biomaterials 2001; 22:323-30. [PMID: 11205435 DOI: 10.1016/s0142-9612(00)00187-3] [Citation(s) in RCA: 133] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A novel organic-inorganic composite membrane was prepared, using tetra ethyl ortho silicate (TEOS) as an inorganic material and chitosan as an organic compound. Equilibrium and oscillatory swelling studies were conducted to investigate swelling behaviors of the membrane according to the pH of the swelling medium. Drug permeation experiments were also performed in phosphate buffer solution of the pH of 2.5 and 7.5, respectively. Lidocaine HCl, sodium salicylate and 4-acetamidophenol were selected as model drugs to examine the effect of ionic property of drug on the permeation behavior. The effects of membrane composition and the external pH on the swelling and the drug permeation behavior of IPN membrane could be summarized as follows; chitosan incorporated into TEOS IPN swelled at pH 2.5 while shrunk at pH 7.5. This swelling behavior was completely reversible and the membrane responded rapidly to the change in environmental pH condition. According to swelling behavior, an increase in pH from 2.5 to 7.5 yielded an increase in the rate of drug permeation because of the shrinking of the incorporated chitosan in TEOS IPN, while decrease in pH resulted in low permeation rate. The optimal TEOS-chitosan ratio for maximum pH-sensitivity existed and drug permeation was influenced not only with the external pH but also with the ionic interactions between the drug and membrane.
Collapse
|
|
24 |
133 |
14
|
Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, Lee JH, Ryoo BY, Park YH, Kwon JM, Oh SY, Lee HR, Kim K, Jung CW, Park K, Kim WS. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006; 37:819-24. [PMID: 16547486 DOI: 10.1038/sj.bmt.1705349] [Citation(s) in RCA: 128] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To determine the role of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) in extranodal NK/T-cell lymphoma patients, we conducted a retrospective analysis. In our previous study, we searched for patients who had received HDC/ASCT and identified 16 eligible patients and compared the treatment outcome with historical control group (n=246). Nine patients received HDC/ASCT in the first (CR1) or second complete remission (CR2), while seven patients received HDC/ASCT as salvage. Twelve of 16 patients achieved or maintained CR after HDC/ASCT. Among the 12 patients, five patients relapsed. Estimated 2-year overall survival (OS) and relapse-free survival (RFS) rates were 71.3+/-12.4% and 25.8+/-14.3%, respectively. There was a tendency of better survival in patients who received HDC/ASCT as compared to those who did not (P=0.091). In subset analysis, patients who underwent HDC/ASCT at CR (P=0.049) and patients with stage III or IV (P=0.001) had a favorable outcome. Patients with NKIPI 3,4 or EUNKTL, who underwent HDC/ASCT had more prolonged survival without statistical significance (P=0.055 and 0.056). In conclusion, HDC/ASCT may be considered as a treatment option for patients with extranodal NK/T-cell lymphoma, especially those in CR, with advanced disease (stage III/IV or EUNKTL) and high NKIPI scores.
Collapse
|
Journal Article |
19 |
128 |
15
|
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 2022; 33:288-298. [PMID: 34921960 PMCID: PMC9447792 DOI: 10.1016/j.annonc.2021.12.002] [Citation(s) in RCA: 124] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 11/12/2021] [Accepted: 12/07/2021] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. PATIENTS AND METHODS ECHELON-2 is a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase III study. We present an exploratory update of the ECHELON-2 study, including an analysis of 5-year PFS per investigator in the intent-to-treat analysis group. RESULTS A total of 452 patients were randomized (1 : 1) to six or eight cycles of A+CHP (N = 226) or CHOP (N = 226). At median follow-up of 47.6 months, 5-year PFS rates were 51.4% [95% confidence interval (CI): 42.8% to 59.4%] with A+CHP versus 43.0% (95% CI: 35.8% to 50.0%) with CHOP (hazard ratio = 0.70; 95% CI: 0.53-0.91), and 5-year overall survival (OS) rates were 70.1% (95% CI: 63.3% to 75.9%) with A+CHP versus 61.0% (95% CI: 54.0% to 67.3%) with CHOP (hazard ratio = 0.72; 95% CI: 0.53-0.99). Both PFS and OS were generally consistent across key subgroups. Peripheral neuropathy was resolved or improved in 72% (84/117) of patients in the A+CHP arm and 78% (97/124) in the CHOP arm. Among patients who relapsed and subsequently received brentuximab vedotin, the objective response rate was 59% with brentuximab vedotin retreatment after A+CHP and 50% with subsequent brentuximab vedotin after CHOP. CONCLUSIONS In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.
Collapse
|
Clinical Trial, Phase III |
3 |
124 |
16
|
Vacanti CA, Paige KT, Kim WS, Sakata J, Upton J, Vacanti JP. Experimental tracheal replacement using tissue-engineered cartilage. J Pediatr Surg 1994; 29:201-4; discussion 204-5. [PMID: 8176592 DOI: 10.1016/0022-3468(94)90318-2] [Citation(s) in RCA: 115] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The authors tested the feasibility of using tissue-engineered cartilage, grown in the shape of cylinders, for replacing large circumferential defects of the cervical trachea in rats. Chondrocytes obtained from the shoulder of newborn calves were seeded onto a synthetic nonwoven mesh, 100 microns thick, of polyglycolic acid fibers 15 microns in diameter, cut into pieces of 2.5 x 4 cm. Twenty cell-polymer constructs were wrapped around silastic tubes and implanted into 10 nude mice for 4 weeks. Specimens were then excised and evaluated grossly and histologically for the presence of new cartilage, and biomechanically for their ability to resist collapse upon application of negative pressure. Six cylinders of tissue-engineered cartilage were then sutured into large circumferential defects created in the cervical tracheas of nude rats to replace the excised trachea. Implantation of cell-polymer constructs resulted in the formation of cylinders of hyaline cartilage. When placed within the lumen of a segment of bowel denuded of its mucosal lining, the hollow cylinders resisted collapse in all instances upon administration of negative 200 mm Hg pressure. The cartilage was grossly and histologically identical to that from which the cells had been initially isolated. Four of the six animals receiving these cartilage cylinders as tracheal replacements survived the procedure and were able to breathe in an unassisted fashion. Three of these animals never recovered fully from the anesthetic and the operation, and expired at 24, 48, and 72 hours. The fourth animal fully recovered from the procedure, and breathed spontaneously for 1 week, with no apparent limitations. Increasing respiratory distress then developed, and the animal died.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
|
31 |
115 |
17
|
Abstract
Fgf-8 is one of the key signaling molecules implicated in the initiation, outgrowth, and patterning of vertebrate limbs. However, it is not clear whether FGF-8 plays similar role in development and regeneration of urodele limbs. We isolated a Fgf-8 cDNA from the Mexican axolotl (Ambystoma mexicanum) through the screening of an embryo cDNA library. The cloned 1.26-kb cDNA contained an open reading frame encoding 212 amino acid residues with 84%, 86%, and 80% amino acid identities to those of Xenopus, chick, and mouse, respectively. By using the above clone as a probe, we examined the temporal and spatial expression patterns of Fgf-8 in developing embryos and in regenerating larval limbs. In developing embryos, Fgf-8 was expressed in the neural fold, midbrain-hindbrain junction, tail and limb buds, pharyngeal clefts, and primordia of maxilla and mandible. In the developing axolotl limb, Fgf-8 began to be expressed in the prospective forelimb region at pre-limb-bud and limb bud stages. Interestingly, strong expression was detected in the mesenchymal tissue of the limb bud before digit forming stages. In the regenerating limb, Fgf-8 expression was noted in the basal layer of the apical epithelial cap (AEC) and the underlying thin layer of mesenchymal tissue during blastema formation stages. These data suggest that Fgf-8 is involved in the organogenesis of various craniofacial structures, the initiation and outgrowth of limb development, and the blastema formation and outgrowth of regenerating limbs. In the developing limb of axolotl, unlike in Xenopus or in amniotes such as chick and mouse, the Fgf-8 expression domain was localized mainly in the mesenchyme rather than epidermis. The unique expression pattern of Fgf-8 in axolotl suggests that the regulatory mechanism of Fgf-8 expression is different between urodeles and other higher species. The expression of Fgf-8 in the deep layer of the AEC and the thin layer of underlying mesenchymal tissue in the regenerating limbs support the previous notion that the amphibian AEC is a functional equivalent of the AER in amniotes.
Collapse
|
|
24 |
115 |
18
|
Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001; 19:81-3. [PMID: 11291836 DOI: 10.1023/a:1006481423298] [Citation(s) in RCA: 108] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Lovastatin, an inhibitor of mevalonate synthesis, demonstrated in vitro antitumor activity against a variety of human cancer cells, especially in gastric adenocarcinoma cells at pharmacologically achievable concentrations. To determine the antitumor activity of this drug in advanced measurable gastric adenocarcinoma as well as to assess the toxicities and the pharmacokinetic features, we carried out a phase II study of high-dose lovastatin. Patients received lovastatin 35 mg/kg/day for 7 consecutive days, with ubiquinone (60 mg qid p.o.) to prevent rhabdomyolysis. The treatment was repeated every 28 days. From March 1996 to January 1997, 16 patients (median age, 57 years; range, 34-68) were entered into the study, 14 of whom were evaluated for response and toxicity. No patient achieved a response. A total of 28 cycles were administered. The median number of cycles was 2 (range, 1 to 4). Anorexia was the most common toxicity (64%), but decreased oral intake was observed only in 3 cycles. Two patients developed myalgia with elevated muscle enzyme. When used in this dosage and schedule, lovastatin does not appear to be effective for patients with advanced gastric adenocarcinoma.
Collapse
|
Clinical Trial |
24 |
108 |
19
|
Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011; 96:658-64. [PMID: 21239517 DOI: 10.1210/jc.2010-1082] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
CONTEXT In Korea, where PTC comprises about 90-95% of the reported thyroid cancers, the prevalence of BRAF(V600E) mutation in papillary thyroid carcinoma (PTC) is above 80%. OBJECTIVE We analyzed the surgical result according to a management guideline based on the BRAF(V600E) mutation status of thyroid nodules. DESIGN A total of 865 thyroid nodules were prospectively analyzed for their cytology and BRAF(V600E) mutation status by pyrosequencing. For the patients who had a diagnosis of atypical cells of undetermined significance (ACUS), we recommended surgery when there was positivity for BRAF(V600E) mutation or the nodules were clinically suspicious. RESULTS Among 865 cases, 504, 141, 54, 140, 10, and 16 were diagnosed as benign, ACUS, suspicious for malignancy, malignant, suspicious for follicular neoplasm, and nondiagnostic, respectively. None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspicious for malignancy, 129 (92.1%) of the 140 malignant, and one (10%) of the 10 suspicious for follicular neoplasm cases showed BRAF(V600E) mutation. Surgery was recommended to all 45 patients with BRAF(V600E) mutation-positive ACUS nodules; among them, 30 patients underwent surgery, 29 had PTC, and one had nodular hyperplasia. All the patients diagnosed as suspicious for malignancy or malignant were advised to undergo an operation, and they turned out to have PTCs regardless of their BRAF(V600E) mutation status. CONCLUSIONS We found that performing BRAF(V600E) mutation analysis on the fine-needle aspiration biopsy specimens was of great help to make a therapeutic decision for thyroid nodules when the fine-needle aspiration biopsy results were equivocal.
Collapse
|
|
14 |
108 |
20
|
Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS, Kim SW. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000; 89:2106-16. [PMID: 11066052 DOI: 10.1002/1097-0142(20001115)89:10<2106::aid-cncr11>3.0.co;2-g] [Citation(s) in RCA: 105] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND This study aimed to define genotypic profile and to describe the clinicopathologic features of nasal-type natural killer (NK)/T-cell lymphoma of nasal and extranasal origin and NK precursor lymphoma. METHODS NK/T-cell lymphomas from the upper aerodigestive tract (n = 45), skin (n = 2), gastrointestinal tract (n = 3), and soft tissue (n = 2) and NK precursor neoplasms (n = 3) were studied. Immunophenotype was analyzed by immunohistochemistry and flow cytometry. In situ hybridization with EBER 1/2 RNA probes was performed. T-Cell Receptor (TCR)-gamma gene rearrangement was analyzed by seminested polymerase chain reaction with heteroduplex analysis. Overall survival rate was correlated with clinicopathologic parameters and compared by Wilcoxon test. RESULTS Clonal TCR-gamma gene rearrangement was detected in 3 of 31 upper aerodigestive and 1 of 2 skin tumors. When immunostained using paraffin embedded tissue, 6 upper aerodigestive lymphomas were negative for CD56 in which 4 cases lacked clonal TCR gene rearrangement. Epstein-Barr virus (EBV) mRNA was detected in 33 upper aerodigestive tumors including 26 of 29 nasal tumors (90%), and 7 of 10 extranasal tumors (70%). There was no histologic, immunophenotypic, or genotypic differences according to the lineage and EBV association in upper aerodigestive lymphomas. Among the patients with upper aerodigestive tumors, overall 1-year survival rate was 41%, and correlated well with the stage (P < 0.05) but not with the size of tumor cells, EBV status, and lineage (P > 0.05). Median survival rate of lymphomas from other sites excluding upper aerodigestive tract was not significantly different from that of upper aerodigestive lymphomas with same stage (P > 0.05). Unlike nasal-type NK/T-cell lymphomas, NK precursor lymphoma involved the bone marrow and lymph nodes at initial presentation or in the course of disease. Tumor cells were positive for TdT in all and myeloid markers in two. TCR gene rearrangement was germ line. CONCLUSIONS Most upper aerodigestive nasal-type NK/T-cell lymphomas among Koreans are genotypically of NK derivation and few belong to T lineage. Presence or absence of EBV has no significant correlation with the histologic changes and the lineage of these lymphomas.
Collapse
|
|
25 |
105 |
21
|
Pearlson GD, Kim WS, Kubos KL, Moberg PJ, Jayaram G, Bascom MJ, Chase GA, Goldfinger AD, Tune LE. Ventricle-brain ratio, computed tomographic density, and brain area in 50 schizophrenics. ARCHIVES OF GENERAL PSYCHIATRY 1989; 46:690-7. [PMID: 2751403 DOI: 10.1001/archpsyc.1989.01810080020003] [Citation(s) in RCA: 100] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
A sample of 50 DSM-III-diagnosed schizophrenics (mean age, 34 years) intentionally biased to contain a relatively high proportion of persistently unemployed persons was compared with a sample of 87 normal volunteers on three computed tomographic measures. These were lateral ventricle-brain ratio, regional brain computed tomographic density values, and brain slice area. Images were made with the same computed tomographic scanner and identical scan parameters. Computed tomographic data were assessed blindly using a computer-linked image array processor and electronic planimeter. Ventricle-brain ratios were significantly higher in schizophrenics, with 28% of the patient sample exceeding 2 SDs of the control mean. Brain area measures were not associated with an enlarged ventricle-brain ratio. Contrary to our prediction, ventricular enlargement was unassociated with most negative symptom ratings, but was correlated with the absence of positive symptoms. A history of abnormal delivery and the presence of left-handedness were significant predictors of an enlarged ventricle-brain ratio on multiple regression analysis. Schizophrenics had a significantly smaller brain slice area compared with normal controls, a finding not attributable to height differences between groups. Brain slice area was inversely correlated with computed tomographic brain density across all subjects. After correction of computed tomographic density values for area using a linear regression model, no significant regional density differences were detectable between normal controls and schizophrenics. Within normal controls there was a significant relationship between social class and brain slice area, but not ventricle-brain ratio.
Collapse
|
|
36 |
100 |
22
|
Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong HS, Kim JA, Nam SJ, Yang JH, Son YI, Baek CH, Han J, Ree HJ, Lee ES, Kim SH, Kim DW, Ahn YC, Huh SJ, Choe YH, Lee JH, Park MH, Kong GS, Park EY, Kang YK, Bang YJ, Paik NS, Lee SN, Kim SH, Kim S, Robbins PD, Tahara H, Lotze MT, Park CH. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12:671-84. [PMID: 11426466 DOI: 10.1089/104303401300057388] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
A phase I dose-escalation clinical trial of peritumoral injections of interleukin 12 (IL-12)-transduced autologous fibroblasts was performed in patients with disseminated cancer for whom effective treatment does not exist. The goals of this study were to assess the safety and toxicities as well as the efficacy, and ancillarily the immunomodulatory effects, of peritumoral IL-12 gene transfer. Primary dermal fibroblasts cultured from the patients were transduced with retroviral vector carrying human IL-12 genes (p35 and p40) as well as the neomycin phosphotransferase gene (TFG-hIL-12-Neo). Patients received four injections at intervals of 7 days. Nine patients were enrolled in this dose-escalation study, with secreted IL-12 doses ranging from 300 ng/24 hr for the first three patients to 1000, 3000, and 5000 ng/24 hr for two patients in each subsequent dosage level. Although a definite statement cannot be made, there appears to be perturbation of systemic immunity. Also, the locoregional effects mediated by tumor necrosis factor alpha (TNF-alpha) and CD8+ T cells were observed with tumor regression. Treatment-related adverse events were limited to mild to moderate pain at the injection site; clinically significant toxicities were not encountered. Transient but clear reductions of tumor sizes were observed at the injected sites in four of nine cases, and at noninjected distant sites in one melanoma patient. Hemorrhagic necrosis of tumors was observed in two melanoma patients. These data indicate that gene therapy by peritumoral injection of IL-12-producing autologous fibroblasts is feasible, and promising in patients with advanced cancer.
Collapse
|
Clinical Trial |
24 |
99 |
23
|
Pearlson GD, Rabins PV, Kim WS, Speedie LJ, Moberg PJ, Burns A, Bascom MJ. Structural brain CT changes and cognitive deficits in elderly depressives with and without reversible dementia ('pseudodementia'). Psychol Med 1989; 19:573-584. [PMID: 2798631 DOI: 10.1017/s003329170002417x] [Citation(s) in RCA: 95] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Twenty-six elderly (greater than 60 yrs) patients with DSM-III major depression were compared to 13 patients with NINCDS/ADRDA probable Alzheimer's disease (AD), and to 31 screened normal controls. Subjects were matched on age and sex. Fifteen of the 26 depressed patients were cognitively impaired on the Mini-Mental State Examination (MMSE) upon admission, but after treatment returned to the normal range. These 15 patients were defined as having the dementia syndrome of depression (DOD). The remaining 11 depressed patients were termed depressed, cognitively normal (DCN). All subjects received standardized cranial CT scans for assessment of ventricular brain ratio (VBR) and CT attenuation numbers. Subjects also received neuropsychological evaluation. CT values for the 26 depressed patients lay between those of AD patients and normal controls. CT values for the DOD subgroup clustered near those of AD patients. Patterns of cognitive deficits and correlations of CT attenuation values with cognitive measures were also similar in AD and DOD. Most patients were reassessed at a mean of two years after initial testing; of the 11 of the 15 DOD re-examined, only one had undergone cognitive decline. By contrast, all AD patients retested had declined significantly. Episodes of DOD and DCN tended to 'breed true'. This study suggests that while patients with DOD may have underlying structural brain abnormalities, obvious short-term progression to AD does not commonly occur.
Collapse
|
|
36 |
95 |
24
|
Kim WS, Perl L, Park JH, Tandianus JE, Dunn NW. Assessment of stress response of the probiotic Lactobacillus acidophilus. Curr Microbiol 2001; 43:346-50. [PMID: 11688799 DOI: 10.1007/s002840010314] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Different aspects of stress response of Lactobacillus acidophilus were investigated. First, the sublethal and lethal levels of bile, heat, and NaCl stresses were determined. They were 0.05% and 0.5% (bile), 53 degrees C and 60 degrees C (heat), and 2% and 18% (NaCl), respectively. To evaluate the effect of each stress at log phase, log-phase cultures were challenged directly with the lethal level of each stress (control) and were compared to log-phase cultures that were pre-exposed to the sublethal level prior to the exposure at the lethal level (test). Some, if not most, of the cells were killed in the control cultures against each of the three stresses. However, in the test cultures, the number of cells that had survived increased significantly. It appears that L. acidophilus is capable of displaying adaptive response to stress. The adaptive response to one stress was also shown to provide cross-protection against different stresses tested. The effect of each stress on stationary-phase cultures was also investigated. In contrast to log-phase culture, stationary-phase culture was inherently resistant to stress.
Collapse
|
|
24 |
89 |
25
|
Park IN, Jegal Y, Kim DS, Do KH, Yoo B, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2008; 33:68-76. [PMID: 18829672 DOI: 10.1183/09031936.00158507] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Most studies of idiopathic nonspecific interstitial pneumonia (NSIP) have primarily studied mortality. In order to clarify the detailed outcome and prognostic markers in idiopathic NSIP, the clinical course with initial radiological and clinical features was analysed. The clinical course of 83 patients who were classified with idiopathic NSIP (72 fibrotic, 11 cellular; 27 males and 56 females; mean+/-sd age 54.4+/-10.1 yrs) was retrospectively analysed. In fibrotic NSIP, 16 (22%) patients died of NSIP-related causes with a median (range) follow-up of 53 (0.3-181) months. Despite the favourable survival (5-yr 74%), patients with fibrotic NSIP were frequently hospitalised with recurrence rate of 36%. Reduced forced vital capacity at 12 months was a predictor of mortality. On follow-up, lung function was improved or stable in approximately 80% of the patients. The extent of consolidation and ground-glass opacity on initial high-resolution computed tomography correlated significantly with serial changes of lung function, and the presence of honeycombing was a predictor of poor prognosis. During follow-up, eight (10%) patients developed collagen vascular disease. In conclusion, the overall prognosis of fibrotic nonspecific interstitial pneumonia was good; however, there were significant recurrences despite initial improvement and a subset of the patients did not respond to therapy. Some patients developed collagen vascular diseases at a later date.
Collapse
|
Journal Article |
17 |
88 |